The Canada Point of Care Molecular Diagnostics Market, valued at USD 350 million in 2024, is projected to reach USD 560 ...

札幌東徳洲会病院は1月21日、膵がんの発がんに関連する主要ドライバー変異（KRASおよびGNASのホットスポット変異）を、少ない反応数で包括的に検出するための6色マルチプレックスデジタルPCRアッセイ法を構築したと発表した。この研究は、同病院医学研究所の小野裕介主任研究員（ゲノム診断研究部部門長）、旭川医科大学内科学講座消化器内科学分野の水上裕輔教授（国立研究開発法人医薬基盤・健康・栄養研究所難病 ...

The system is intended for use in urgent care clinics, primary care settings, physician office laboratories, and pharmacies.

Support vector machines improve classification by mapping inseparable signals into higher-dimensional spaces. Random forest models, through ensemble decision trees, increase robustness against ...

NEW YORK – Lex Diagnostics said on Monday that it has obtained 510 (k) clearance and CLIA waiver from the US Food and Drug Administration for its Velo point-of-care molecular diagnostic system and an ...

The FDA has cleared a multiplex polymerase chain reaction test designed to detect 11 clinically relevant gastrointestinal pathogens from a single stool sample.The Xpert GI Panel (Cepheid) can identify ...

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

LEX Diagnostics, a Cambridgeshire-based innovator in molecular diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for a platform that could ...

In RNA-seq library preparation, selecting the appropriate number of PCR cycles is a critical balancing act to avoid overcycling.

The FDA clearance represents a pivotal step in LEX Diagnostics’ strategy and underscores the company’s commitment to advancing point-of-care testing with accurate, timely, and clinically actionable ...

Global Molecular Infectious Disease Testing Market OverviewThe global molecular infectious disease testing market is ...

LEX Diagnostics receives US FDA 510(k) clearance and CLIA waiver for LEX VELO system: Cambridgeshire, UK Tuesday, February 17, 2026, 17:00 Hrs [IST] LEX Diagnostics, a leading inn ...